search icon
drma-img

Dermata Therapeutics Inc, Common Stock

DRMA

NAQ

$1.44

+$0.06

(4.35%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
203.03K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.79
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1 L
$8.65 H
$1.44

About Dermata Therapeutics Inc, Common Stock

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameDRMASectorS&P500
1-Week Return5.88%0.31%-1.26%
1-Month Return34.58%0.6%-4.16%
3-Month Return11.63%-9.44%-0.46%
6-Month Return-34.25%-5.15%3.58%
1-Year Return-78.81%0.33%22.47%
3-Year Return-99.61%4.53%25.13%
5-Year Return-99.88%35.98%77.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue1.35K322.00---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":23.76,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit(1.35K)(322.00)---[{"date":"2019-12-31","value":-135500,"profit":false},{"date":"2020-12-31","value":-32200,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)---[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses4.47M3.17M7.86M9.67M8.04M[{"date":"2019-12-31","value":46.21,"profit":true},{"date":"2020-12-31","value":32.8,"profit":true},{"date":"2021-12-31","value":81.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.12,"profit":true}]
Operating Income(4.47M)(3.17M)(7.86M)(9.67M)(8.04M)[{"date":"2019-12-31","value":-447060800,"profit":false},{"date":"2020-12-31","value":-317285300,"profit":false},{"date":"2021-12-31","value":-785686400,"profit":false},{"date":"2022-12-31","value":-967448600,"profit":false},{"date":"2023-12-31","value":-804190600,"profit":false}]
Total Non-Operating Income/Expense(501.50K)(260.95K)(91.23K)127.15K450.66K[{"date":"2019-12-31","value":-111.28,"profit":false},{"date":"2020-12-31","value":-57.9,"profit":false},{"date":"2021-12-31","value":-20.24,"profit":false},{"date":"2022-12-31","value":28.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(4.72M)(3.24M)(7.90M)(9.61M)(7.79M)[{"date":"2019-12-31","value":-472135600,"profit":false},{"date":"2020-12-31","value":-323653000,"profit":false},{"date":"2021-12-31","value":-790247700,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-779469000,"profit":false}]
Income Taxes250.75K197.27K45.61K(9.67K)(8.04K)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":78.67,"profit":true},{"date":"2021-12-31","value":18.19,"profit":true},{"date":"2022-12-31","value":-3.86,"profit":false},{"date":"2023-12-31","value":-3.21,"profit":false}]
Income After Taxes(4.97M)(3.43M)(7.95M)(9.60M)(7.79M)[{"date":"2019-12-31","value":-497210400,"profit":false},{"date":"2020-12-31","value":-343379900,"profit":false},{"date":"2021-12-31","value":-794809000,"profit":false},{"date":"2022-12-31","value":-960123851,"profit":false},{"date":"2023-12-31","value":-778664809,"profit":false}]
Income From Continuous Operations(4.72M)(3.24M)(7.90M)(9.61M)(7.33M)[{"date":"2019-12-31","value":-472135600,"profit":false},{"date":"2020-12-31","value":-323653000,"profit":false},{"date":"2021-12-31","value":-790247700,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-733031900,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(4.97M)(3.43M)(7.95M)(9.61M)(7.79M)[{"date":"2019-12-31","value":-497210400,"profit":false},{"date":"2020-12-31","value":-343379900,"profit":false},{"date":"2021-12-31","value":-794809000,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-779469000,"profit":false}]
EPS (Diluted)(0.74)(1.21)(29.12)(14.72)(3.65)[{"date":"2019-12-31","value":-74.37,"profit":false},{"date":"2020-12-31","value":-120.61,"profit":false},{"date":"2021-12-31","value":-2912,"profit":false},{"date":"2022-12-31","value":-1472,"profit":false},{"date":"2023-12-31","value":-365,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

DRMA
Cash Ratio 3.16
Current Ratio 3.44

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DRMA
ROA (LTM) -90.68%
ROE (LTM) -173.01%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DRMA
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DRMA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.62
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.58

FAQs

What is Dermata Therapeutics Inc share price today?

Dermata Therapeutics Inc (DRMA) share price today is $1.44

Can Indians buy Dermata Therapeutics Inc shares?

Yes, Indians can buy shares of Dermata Therapeutics Inc (DRMA) on Vested. To buy Dermata Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DRMA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Dermata Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Dermata Therapeutics Inc (DRMA) via the Vested app. You can start investing in Dermata Therapeutics Inc (DRMA) with a minimum investment of $1.

How to invest in Dermata Therapeutics Inc shares from India?

You can invest in shares of Dermata Therapeutics Inc (DRMA) via Vested in three simple steps:

  • Click on Sign Up or Invest in DRMA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Dermata Therapeutics Inc shares
What is Dermata Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Dermata Therapeutics Inc (DRMA) is $8.65. The 52-week low price of Dermata Therapeutics Inc (DRMA) is $1.

What is Dermata Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Dermata Therapeutics Inc (DRMA) is

What is Dermata Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Dermata Therapeutics Inc (DRMA) is 0.62

What is Dermata Therapeutics Inc dividend yield?

The dividend yield of Dermata Therapeutics Inc (DRMA) is 0.00%

What is the Market Cap of Dermata Therapeutics Inc?

The market capitalization of Dermata Therapeutics Inc (DRMA) is $2.94M

What is Dermata Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Dermata Therapeutics Inc is DRMA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top